Capital Bluecross Vitamin D Testing Coverage

Coverage Criteria and Medical Necessity

Medically necessary indications

Covered when criteria below are met

25-hydroxyvitamin D coverage: 25-hydroxyvitamin D (25[OH]D) serum testing meets coverage criteria for individuals with an underlying disease or condition specifically associated with vitamin D deficiency or decreased bone density or for individuals suspected of hypervitaminosis or with documented vitamin D deficiencyfrequency: no more than one test every six months

See Note 1 for list of qualifying conditions (e.g., malabsorption, bariatric surgery, chronic kidney disease stage III-V, liver disease, osteoporosis, rickets, medications that lower vitamin D)

D2/D3 fraction testing: Testing for D2 and D3 fractions as part of total 25-hydroxyvitamin D analysis meets coverage criterianone

D2/D3 fractions measured as part of total 25OHD per Note 1

1,25-dihydroxyvitamin D coverage: 1,25-dihydroxyvitamin D serum testing meets coverage criteria for evaluation or treatment of conditions associated with defects in vitamin D metabolismnone

See Note 2 for specific indications (e.g., disorders of calcium metabolism, familial hypophosphatemia, Fanconi syndrome, renal disease, sarcoidosis)

Not medically necessary / Not covered

Not covered

Not covered indications: Measurement of serum 1,25-dihydroxyvitamin D to screen for vitamin D deficiency and routine serum screening for vitamin D deficiency in asymptomatic individuals or during general encounters do not meet coverage criterianone

These uses are explicitly excluded from coverage per the policy

Indication-based testing

Covered when clinical indications or guideline-based scenarios are present

Indications supportive of testing: Testing is indicated for patients with hip fracture or other fractures (especially age ≥50 with hip fracture), bone diseases where correction of vitamin D status may improve outcomes, symptomatic vitamin D deficiency (e.g., hypocalcemia, bone disease), malabsorption syndromes, patients on therapies that increase vitamin D catabolism (antiseizure drugs, long-term glucocorticoids, chemotherapy), and for baseline and follow-up assessment in bariatric surgery patients

Sources include Holick, RACGP, NHS, AACE and other guideline statements

Retesting/Monitoring

Retesting/monitoring covered when ALL of the following are met

Retest timing and situations: Retesting is appropriate no earlier than 3 months after initiating vitamin D supplementation or after a dose change; repeat measurement should be considered for symptomatic deficiency, malabsorption while on therapy, very low baseline 25(OH)D, or patients receiving sequential antiresorptive therapy>=3 months usually

RACGP and Manchester Trust advise against retesting within 3 months and preferably not within 6 months in most patients; NHS guidance allows retesting at 3-6 months in select patients

Routine screening

Population screening stance

Routine screening discouraged: Multiple professional bodies recommend against routine population screening for 25(OH)D in asymptomatic individuals; routine universal screening is not supported by current evidence

Endocrine Society (2024) and USPSTF conclude against or state insufficient evidence for routine screening; AAP advises targeted screening only

The policy excludes routine screening in asymptomatic individuals and specifies that measurement of serum 1,25-dihydroxyvitamin D to screen for vitamin D deficiency does not meet coverage criteria. As stated in the indications section, 1,25-dihydroxyvitamin D testing is reserved for evaluation or treatment of disorders of vitamin D metabolism and is not covered when ordered solely for population or routine deficiency screening in asymptomatic patients.

Multiple guideline sources referenced in the policy advise against routine population screening for vitamin D in asymptomatic individuals. The Endocrine Society (2024) explicitly suggests against routine 25(OH)D testing across adult age groups and during pregnancy, the USPSTF concludes evidence is insufficient to recommend general population screening, and the Manchester University NHS Trust recommends treating high‑risk asymptomatic individuals empirically without measurement. Consequently, routine population screening is not recommended and may be excluded from coverage absent a documented qualifying clinical indication.

The policy clarifies that 1,25-dihydroxyvitamin D is the active form used for evaluation of defects in vitamin D metabolism and is covered only for those specific indications (see Note 2). It also restates that measurement of serum 1,25-dihydroxyvitamin D for routine screening of vitamin D deficiency is not covered and should not be used as a screening test in asymptomatic populations.

Testing as part of routine screening in general asymptomatic adult populations is not supported by guideline evidence cited in the policy and is considered not indicated unless specific risk factors or clinical scenarios are documented. The policy reflects guideline positions (e.g., Endocrine Society, USPSTF) and states that routine screening for 25(OH)D in asymptomatic individuals is discouraged and may not meet coverage criteria.

Specific Clinical Indications Supported by Evidence

Assessment of vitamin D status (25OHD)

Assessment of vitamin D status (25OHD): Assessment of vitamin D status (25-hydroxyvitamin D) is covered for patients with listed conditions associated with deficiency or decreased bone density, suspected vitamin D toxicity, or evaluation/treatment of defects in vitamin D metabolismfrequency: no more than one test every six months

Refer to Note 1 for the full list of qualifying conditions (e.g., malabsorption, bariatric surgery, CKD stage III-V, osteomalacia, rickets, sarcoidosis)

Assessment for fractures, bone disease, malabsorption, symptomatic deficiency, and medication-related risk

Fractures, bone disease, malabsorption and medication-related indications: Assessment of vitamin D status is covered for patients with fractures (especially hip), bone diseases where correction may improve outcomes, malabsorption syndromes, symptomatic deficiency, and patients on medications associated with increased vitamin D catabolism; baseline and follow-up testing may be appropriate for bariatric surgery patients and those on antiresorptive therapy

Testing Frequency and Retesting Guidance

25-hydroxyvitamin D — general frequency limit

Maximum covered frequencyNo more than one 25-hydroxyvitamin D test every six months (one test per 6 months).

Applies toSerum 25-hydroxyvitamin D (25OHD) testing billed with applicable procedure codes (e.g., CPT 82306 or equivalent).

RationaleLimits intended to align testing with guideline-based monitoring and to avoid unnecessary repeat measurements in stable patients.

25‑OH vitamin D — retest timing and monitoring

Do not retest sooner than 3 monthsDo not retest 25‑OH vitamin D within 3 months of initiating vitamin D replacement.

Avoid repeat within 3–6 monthsIn most patients, avoid repeat testing within 3–6 months; repeat measurement should be considered for symptomatic deficiency, malabsorption on therapy, very low baseline levels, or patients receiving sequential antiresorptive therapy.

Procedure Codes and Medical Coding Guidance

Applicable CPT/HCPCS procedure codesmixed

No codes listed

Applicable procedure codesCPT

82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed.
82652	Vitamin D; 1, 25 dihydroxy, includes fraction(s), if performed.
0038U	Vitamin D, 25 hydroxy D2 and D3, by LC-MS/MS, serum microsample, quantitative (Proprietary test: Sensieva ™ Droplet 25OH Vitamin D2/D3 Microvolume LC/MS Assay)

Applicable CPT/HCPCS Procedure CodesCPT

82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed.
82652	Vitamin D; 1, 25 dihydroxy, includes fraction(s), if performed.
0038U	Vitamin D, 25 hydroxy D2 and D3, by LC-MS/MS, serum microsample, quantitative (Proprietary test: Sensieva ™ Droplet 25OH Vitamin D2/D3 Microvolume LC/MS Assay)

Vitamin D deficiency and toxicity thresholds

Deficiency thresholdSerum 25OHD <20 ng/mL is considered vitamin D deficiency.

Suboptimal/insufficientSome organizations consider <30 ng/mL as insufficient; experts commonly target 20–40 ng/mL.

Toxicity thresholdVitamin D toxicity is rare and occurs when 25OHD >200 ng/mL (equivalent to >500 nmol/L).

Vitamin D sufficiency thresholds (examples from guidelines)

ROS thresholds (nmol/L)Royal Osteoporosis Society: <25 nmol/L = deficient; 25–50 nmol/L = may be inadequate; >50 nmol/L = sufficient for almost the whole population.

AACE target (ng/mL)

Provider Actions, Documentation, and Billing Rules

Denial Risk

Procedure codes — billing and denial risk

Procedure codes listed in this policy must be used when billing. Claims submitted with procedure codes that do not match the covered CPT/HCPCS codes below, or that lack required supporting documentation, may be denied.

Use the listed procedure codes when billing: CPT 82306, CPT 82652, and proprietary assay code 0038U.
Claims using codes not matching the covered CPT/HCPCS codes are at risk for denial if clinical documentation does not support medical necessity.

Documentation Required

Required clinical documentation

Documentation must show the underlying disease/condition or specific clinical suspicion prompting vitamin D testing and must include relevant clinical data at the time of order.

Document the clinical indication or underlying disease associated with vitamin D deficiency (see policy Note 1 list: e.g., malabsorption, bariatric surgery, chronic kidney disease stages III–V/ESRD, osteomalacia, osteoporosis, certain medications, etc.).

Ordering, Documentation, and Operational Requirements

Prior Authorization

Ordering: test when qualifying clinical conditions are present

Order 25‑hydroxyvitamin D testing when the patient's clinical context fits qualifying conditions listed in Note 1 (for example: chronic glucocorticoid therapy >3 months, chemotherapy, malabsorption, bariatric surgery, fractures, or biochemical indicators of abnormal calcium/phosphorus/PTH).

Chronic glucocorticoid use (>3 months) or chemotherapy
Malabsorption syndromes or bariatric surgery patients
Biochemical indicators: abnormal calcium/phosphorus, elevated alkaline phosphatase, out‑of‑range PTH

Documentation Required

Ordering: document indication; empiric treatment option for asymptomatic high‑risk patients

Document the clinical indication on the order; note that asymptomatic high‑risk individuals may be treated empirically without testing per local recommendations such as the Manchester Trust guidance.

Record the reason for testing on the requisition or order

Non-covered Indications

The policy lists tests and indications that are not covered, including routine screening of asymptomatic individuals and the use of 1,25-dihydroxyvitamin D for population or routine deficiency screening. Coverage is limited to clinically justified indications such as disorders of vitamin D metabolism (for 1,25-dihydroxyvitamin D) and identified high‑risk or symptomatic conditions for 25‑hydroxyvitamin D.

The policy aligns with major guideline bodies in discouraging routine screening for 25(OH)D in asymptomatic individuals. The Endocrine Society (2024) recommends against routine population testing across adult age groups and during pregnancy, and the USPSTF reports insufficient evidence to support universal screening. As such, routine screening for 25(OH)D in asymptomatic individuals is not supported and is discouraged in this coverage policy.

Within the excerpt provided there are no additional explicit tests or clinical indications labeled as not covered beyond those already stated (routine population screening and use of 1,25-dihydroxyvitamin D for screening). The listed CPT/HCPCS procedure codes (e.g., 82306, 82652, 0038U) are provided for billing reference but do not, in this excerpt, add further not‑covered items.

Definitions and Test Terminology

25(OH)D / 25OHD — definition

Definition — 25(OH)D / 25OHD25(OH)D (25‑Hydroxyvitamin D) is the predominant circulating form of vitamin D used to assess vitamin D status.

SynonymsAlso referred to as 25OHD or 25‑hydroxyvitamin D in laboratory and guideline documents.

Clinical usePreferred analyte for evaluating vitamin D status due to greater stability and longer half-life compared with active metabolites.

1,25-dihydroxyvitamin D — definition and use

Definition — 1,25-dihydroxyvitamin D1,25‑dihydroxyvitamin D (calcitriol) is the metabolically active hormonal form of vitamin D with a short circulating half-life; used to evaluate defects in vitamin D metabolism and select disorders of calcium/phosphate homeostasis.

Not for routine status assessment

Background and Clinical Context

The policy and supporting background describe that 25-hydroxyvitamin D (25[OH]D) is the predominant and more stable circulating form used to assess vitamin D status and is the preferred test for that purpose. In contrast, 1,25-dihydroxyvitamin D (calcitriol) is the metabolically active form with a much shorter half‑life and is reserved for evaluation of disorders of vitamin D metabolism rather than routine status assessment.